Results 181 to 190 of about 10,984,262 (303)

Peroxidasin enables melanoma immune escape by inhibiting natural killer cell cytotoxicity

Molecular Oncology, EarlyView.
Peroxidasin (PXDN) is secreted by melanoma cells and binds the NK cell receptor NKG2D, thereby suppressing NK cell activation and cytotoxicity. PXDN depletion restores NKG2D signaling and enables effective NK cell–mediated melanoma killing. These findings identify PXDN as a previously unrecognized immune evasion factor and a potential target to improve
Hsu‐Min Sung, David Bickel, Lena C. M. Krause, Daria Ezeriņa, Christian Ickes, Julian Wojtachnia, Christine S. Gibhardt, Magdalena Shumanska, Khadija Wahni, Andrea Paluschkiwitz, Julia Malo Pueyo, Ekaterina Baranova, Wim Vranken, Hedwig Stanisz, Ioana Stejerean‐Todoran, Michael P. Schön, Joris Messens, Ivan Bogeski   +17 more
wiley   +1 more source

Research on infrastructure network protection strategy based on bayesian stackelberg game under asymmetric conditions. [PDF]

Sci Rep
Zhang J, Gao Y, Kang W, Tian W, Li Y.
europepmc   +1 more source

Creating strategy by design [PDF]

, 2009
Carlopio, James R.
core  

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

Molecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris, Vasiliki Siozopoulou, Léon C van Kempen, Anne Sieben, Ella Roelant, Stig Hellemans, Elyne Backx, Laure Sorber, Koen De Winne, Senada Koljenović, Karen Zwaenepoel   +10 more
wiley   +1 more source

Guide to developing research recruitment strategies with the experts. [PDF]

BMJ Neurol Open
Ramdharry G, Rizig M, Osman B.
europepmc   +1 more source

DEVELOPMENT STRATEGY: CO-BRANDING [PDF]

, 2011
Lezhnina I.
core  

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

Molecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang, Dong Jun Koo, Peter M. Tessier, Greg M. Thurber   +3 more
wiley   +1 more source

Designing Scientific Advisory Committees for a Complex World

Global Challenges, 2018
Steven J. Hoffman, Trygve Ottersen, Prativa Baral, Patrick Fafard   +3 more
doaj   +1 more source

Identifying and avoiding design related biases in observational studies using the target trial framework. [PDF]

BMJ Med
Hansford HJ, Islam N, Lee H, Dickerman BA, Cashin AG.   +4 more
europepmc   +1 more source

STRATEGIST'S TOOLKIT: STRATEGY MAPS [PDF]

, 2013
Morgun, M., Vishnevskaya, K.
core